Evaluation of safety and immunogenicity of feline vaccines with reduced volume.

Dominique Jas, Valérie Frances-Duvert, Sylvie Brunet, Frantz Oberli, Pierre-Michel Guigal, Hervé Poulet

Vaccine 2021 Feb 12

filter terms:

A non adjuvanted vaccine against feline herpesvirus, feline calicivirus, feline panleucopenia and feline leukemia has been formulated in reduced volume (0.5 ml) with the same antigen content as the conventional 1 ml presentation. This paper reports studies evaluating the safety and the immunogenicity of this reduced volume vaccine in comparison with the conventional volume vaccine. The safety of both vaccines was evaluated in a small sized laboratory trial. It was further tested in a randomized controlled field trial on a total of 398 cats. Immediate and delayed local and systemic adverse events were monitored after vaccination. The immunogenicity of each vaccine was also checked by serological antibody responses against the vaccines antigens during the laboratory trial. These studies showed that the 0.5 ml vaccine was well tolerated in cats, inducing less local events, while keeping the same immunogenicity as the corresponding 1 ml vaccine. Reducing the volume of the vaccine is a way to improve the convenience of administration and to help following vaccination guidelines with the aim of reducing the incidence of adverse events following vaccination. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Dominique Jas, Valérie Frances-Duvert, Sylvie Brunet, Frantz Oberli, Pierre-Michel Guigal, Hervé Poulet. Evaluation of safety and immunogenicity of feline vaccines with reduced volume. Vaccine. 2021 Feb 12;39(7):1051-1057